• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gossamer Bio, Inc. - Common Stock (NQ:GOSS)

0.5007 -0.0211 (-4.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gossamer Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
March 03, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm
March 01, 2026
From The Schall Law Firm
Via Business Wire
These stocks are the most active in today's session ↗
February 25, 2026
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session. ↗
February 25, 2026
Via Chartmill
News headline image
Exploring Gossamer Bio's Earnings Expectations ↗
May 14, 2025
 
Via Benzinga
In today's session, these stocks are experiencing unusual volume. ↗
February 24, 2026
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity. ↗
February 23, 2026
Via Chartmill
News headline image
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? ↗
February 23, 2026
Gossamer Bio’s seralutinib did not achieve the predefined statistical bar for its main goal in the phase 3 PROSERA trial. 
Via Stocktwits
These stocks are gapping in today's session ↗
February 23, 2026
Via Chartmill
News headline image
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
February 23, 2026
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2026
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 09, 2025
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio to Participate in Upcoming Investor Conferences
November 24, 2025
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 07, 2025
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio to Participate in Upcoming Investor Conferences
November 07, 2025
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
November 05, 2025
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension
September 25, 2025
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
September 22, 2025
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2025
From Gossamer Bio, Inc.
Via Business Wire
News headline image
This Saia Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗
September 10, 2025
 
Via Benzinga
News headline image
Gossamer Bio to Present at Upcoming Investor Conferences
August 29, 2025
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2025
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update
August 05, 2025
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
July 14, 2025
 
Via Benzinga
News headline image
Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH
June 16, 2025
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream ↗
June 13, 2025
Via Stocktwits
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study
May 15, 2025
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025
May 12, 2025
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 15, 2025 ↗
May 15, 2025
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap